bluebird bio (LSE:0HOH) - Hisse Senedi Fiyatı, Haberler ve Analizler

0HOH Stoklara Genel Bakış

Bir biyoteknoloji şirketi olan bluebird bio, Inc. Amerika Birleşik Devletleri'nde ağır genetik hastalıkların tedavisi için gen terapileri araştırmakta, geliştirmekte ve ticarileştirmektedir. Daha fazla detay

0HOH temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 95.8% daha düşük bir oranda işlem görüyor

Gelirin yılda 41.53% oranında artması öngörülüyor

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

1 yıldan az nakit akışı var

Negatif hissedar öz sermayesi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

+ 2 daha fazla risk

bluebird bio, Inc. Rakipler

Arecor Therapeutics

AIM:AREC

UK£28.9m

Avacta Group

AIM:AVCT

UK£168.3m

Tissue Regenix Group

AIM:TRX

UK£41.0m

BSF Enterprise

LSE:BSFA

UK£3.0m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti bluebird bio
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.36
52 Haftanın En Yüksek Seviyesi	US$5.53
52 Haftanın En Düşük Seviyesi	US$0.29
Beta	0.80
11 Aylık Değişim	-27.32%
3 Aylık Değişim	-40.60%
1 Yıllık Değişim	-90.67%
33 Yıllık Değişim	-96.48%
5 Yıllık Değişim	-99.52%
Halka arzdan bu yana değişim	-99.82%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	0HOH	GB Biotechs	GB Pazar
7D	20.4%	1.5%	1.7%
1Y	-90.7%	-16.3%	8.4%

Getiri vs. Endüstri: 0HOH geçen yıl % -16.3 oranında getiri sağlayan UK Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: 0HOH geçen yıl % 8.4 oranında getiri sağlayan UK Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 0HOH's price volatile compared to industry and market?
0HOH volatility
0HOH Average Weekly Movement	12.9%
Biotechs Industry Average Movement	9.0%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: 0HOH hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 0HOH 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala UK hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1992	282	Andrew Obenshain	www.bluebirdbio.com

Bir biyoteknoloji şirketi olan bluebird bio, Inc, Amerika Birleşik Devletleri'nde tedavi edici ağır genetik hastalıklar için gen terapileri araştırmakta, geliştirmekte ve ticarileştirmektedir. Şirketin ağır genetik hastalıklara yönelik ürün adayları arasında transfüzyona bağlı ß-talasemi tedavisi için ZYNTEGLO (betibeglogene autotemcel); orak hücre hastalığı (SCD) tedavisi için lovotibeglogene autotemcel; ve serebral adrenolökodistrofi tedavisi için SKYSONA (elivaldogene autotemcel) bulunmaktadır. Klinik geliştirme programları arasında SCD hastalarının tedavisinde lovo-cel'in güvenliğini ve etkinliğini değerlendirmek için HGB-205, HGB-206 ve HGB-210; ve ß-talasemi hastalarının tedavisinde beti-cel'in güvenliğini ve etkinliğini değerlendirmek için HGB-204, HGB-205, HGB-207 ve HGB-212 yer almaktadır.

bluebird bio, Inc. Temel Bilgiler Özeti

bluebird bio'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
0HOH temel i̇stati̇sti̇kler
Piyasa değeri	US$71.94m
Kazançlar(TTM)	-US$292.82m
Gelir(TTM)	US$53.12m

1.4x

P/S Oranı

-0.2x

F/K Oranı

0HOH aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
0HOH gelir tablosu (TTM)
Gelir	US$53.12m
Gelir Maliyeti	US$78.78m
Brüt Kâr	-US$25.66m
Diğer Giderler	US$267.16m
Kazançlar	-US$292.82m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.51
Brüt Marj	-48.31%
Net Kâr Marjı	-551.25%
Borç/Özkaynak Oranı	-1,394.4%

0HOH uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

0HOH Stoklara Genel Bakış

Ödüller

Risk Analizi

bluebird bio, Inc. Rakipler

AIM:AREC

UK£28.9m

AIM:AVCT

UK£168.3m

AIM:TRX

UK£41.0m

LSE:BSFA

UK£3.0m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.66 loss in 3Q 2023)

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

Recent updates

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.66 loss in 3Q 2023)

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Now 41% undervalued after recent price drop

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Revenue and earnings growth

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.94 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Now 20% undervalued after recent price drop

New minor risk - Insider selling

President recently sold US$60k worth of stock

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$1.36 loss in 2Q 2022)

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

First quarter 2023 earnings released: EPS: US$0.21 (vs US$1.66 loss in 1Q 2022)

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.94 loss per share (vs US$2.23 loss in 3Q 2021)

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold US$78k worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold US$96k worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer

CEO & Director recently sold US$74k worth of stock

bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022